Skip to main
KYTX

KYTX Stock Forecast & Price Target

KYTX Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. The recent Phase 1 COMPARE data presented at EULAR showed positive results for their autologous CD19 CAR T-cell product candidate, KYV-101, in treating rheumatoid arthritis. With their promising early-stage momentum and a strong clinical and translational package, their potential to successfully address multiple indications suggests an upside potential. With the current positive outlook, the stock presents a favorable investment opportunity.

Bears say

Kyverna Therapeutics is facing challenges in its valuation and risks as evidenced by its enterprise value of only $2B and a price objective of $25 per share. With only a 1% terminal growth rate and low probabilities of approval for its product candidate in various autoimmune diseases, there is a high risk of failure to generate positive data or approval and long-term dilution risk. These factors suggest a negative outlook for the company's stock.

KYTX has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kyverna Therapeutics Inc (KYTX) Forecast

Analysts have given KYTX a Buy based on their latest research and market trends.

According to 4 analysts, KYTX has a Buy consensus rating as of Jul 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kyverna Therapeutics Inc (KYTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.